Skip to content

Study · Measured the body's own peptide · 2019

2 results

Effect of intracanal medicaments on matrix metalloproteinase-9 and vasoactive intestinal peptide secretion in periapical lesions of re-treated canals: a randomized controlled clinical study.

Özdemir MB, Karataş E, Albayrak M, Bayır Y

Clinical oral investigations15 Jun 2018Cited by 7 (Europe PMC)

PMID29948282 (opens in a new tab)DOI10.1007/s00784-018-2517-8 (opens in a new tab)PepBankPUB-29948282
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In patients with periapical lesions, gender and smoking habits had no effect on the body's own VIP levels before or after treatment.

    In plain wordsIn patients with periapical lesions, gender and smoking did not change natural VIP levels in the lesion fluid before or after treatment.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeEffect of gender and smoking on periapical VIP levels
    Study

    n = 60

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels.
    1 context sentence
    Summary · context
    A total of 60 patients were randomly divided into two groups that were to receive different medications.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelRandomized controlled trialOther

    In patients with periapical lesions of re-treated canals, the body's own VIP in periapical interstitial fluid was higher after calcium hydroxide medication than before treatment.

    In plain wordsIn patients with periapical lesions, natural VIP levels in the lesion fluid were higher after calcium hydroxide medication than before it.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePeriapical VIP level after calcium hydroxide medication
    Study

    n: not reported in source

    Comparator
    Pre-treatment level
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Intragroup analyses revealed that in the Ca(OH)2 group, the post-treatment VIP level was found to be significantly higher than the pre-treatment VIP level.
    1 context sentence
    Summary · context
    A total of 60 patients were randomly divided into two groups that were to receive different medications.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.